From nicotine to the cholinergic anti-inflammatory reflex – Can nicotine alleviate the dysregulated inflammation in COVID-19?
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Journal of Immunotoxicology
- Vol. 18 (1) , 23-29
Abstract
The coronavirus SARS-CoV-2 of 2019 (COVID-19) causes a pandemic that has been diagnosed in more than 70 million people worldwide. Mild-to-moderate COVID-19 symptoms include coughing, fever, myalgia, shortness of breath, and acute inflammatory lung injury (ALI). In contrast, acute respiratory distress syndrome (ARDS) and respiratory failure occur in patients diagnosed with severe COVID-19. ARDS is mediated, at least in part, by a dysregulated inflammatory response due to excessive levels of circulating cytokines, a condition known as the “cytokine-storm syndrome.” Currently, there are FDA-approved therapies that attenuate the dysregulated inflammation that occurs in COVID-19 patients, such as dexamethasone or other corticosteroids and IL-6 inhibitors, including sarilumab, tocilizumab, and siltuximab. However, the efficacy of these treatments have been shown to be inconsistent. Compounds that activate the vagus nerve-mediated cholinergic anti-inflammatory reflex, such as the α7 nicotinic acetylcholine receptor agonist, GTS-21, attenuate ARDS/inflammatory lung injury by decreasing the extracellular levels of high mobility group box-1 (HMGB1) in the airways and the circulation. It is possible that HMGB1 may be an important mediator of the “cytokine-storm syndrome.” Notably, high plasma levels of HMGB1 have been reported in patients diagnosed with severe COVID-19, and there is a significant negative correlation between HMGB1 plasma levels and clinical outcomes. Nicotine can activate the cholinergic anti-inflammatory reflex, which attenuates the up-regulation and the excessive release of pro-inflammatory cytokines/chemokines. Therefore, we hypothesize that low molecular weight compounds that activate the cholinergic anti-inflammatory reflex, such as nicotine or GTS-21, may represent a potential therapeutic approach to attenuate the dysregulated inflammatory responses in patients with severe COVID-19.Keywords
Funding Information
- Error! Hyperlink reference not valid.
This publication has 76 references indexed in Scilit:
- Inhibition of extracellular HMGB1 attenuates hyperoxia-induced inflammatory acute lung injuryRedox Biology, 2014
- High Mobility Group Box–1 Mediates Hyperoxia-Induced Impairment of Pseudomonas aeruginosa Clearance and Inflammatory Lung Injury in MiceAmerican Journal of Respiratory Cell and Molecular Biology, 2013
- α7 Nicotinic acetylcholine receptor agonist GTS-21 attenuates ventilator-induced tumour necrosis factor-α production and lung injuryBritish Journal of Anaesthesia, 2011
- Protective Effect of Nicotine on Lipopolysaccharide-Induced Acute Lung Injury in MiceRespiration, 2010
- The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammationJournal of Leukocyte Biology, 2009
- Selective α7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis*Critical Care Medicine, 2007
- Physiology and immunology of the cholinergic antiinflammatory pathwayJournal of Clinical Investigation, 2007
- Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammationNature, 2002
- Safety, Pharmacokinetics, and Effects on Cognitive Function of Multiple Doses of GTS-21 in Healthy, Male VolunteersNeuropsychopharmacology, 2002
- Interleukin-6–Induced Protection in Hyperoxic Acute Lung InjuryAmerican Journal of Respiratory Cell and Molecular Biology, 2000